{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.21","upperLimit":"24.82","value":"20.8"},{"groupId":"OG001","lowerLimit":"12.20","upperLimit":"18.99","value":"15.4"},{"groupId":"OG002","lowerLimit":"21.23","upperLimit":"38.48","value":"29.3"},{"groupId":"OG003","lowerLimit":"18.68","upperLimit":"35.68","value":"26.5"},{"groupId":"OG004","lowerLimit":"17.69","upperLimit":"27.30","value":"22.2"},{"groupId":"OG005","lowerLimit":"12.42","upperLimit":"20.93","value":"16.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"461"},{"groupId":"OG001","value":"462"},{"groupId":"OG002","value":"116"},{"groupId":"OG003","value":"113"},{"groupId":"OG004","value":"306"},{"groupId":"OG005","value":"312"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants, who had an objective response. Objective response was defined as either a complete response (CR) or partial response (PR) as determined by the investigator with use of Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). Objective response in this study did not need to be a confirmed response. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. ORR=CR+PR","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m\\^2), paclitaxel 175 mg/m\\^2, or docetaxel 75 mg/m\\^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.","id":"OG000","title":"Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)"},{"description":"Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.","id":"OG001","title":"Atezolizumab"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC2/3","id":"OG002","title":"IC2/3 Chemotherapy"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC2/3","id":"OG003","title":"IC2/3 Atezolizumab"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC1/2/3","id":"OG004","title":"IC1/2/3 Chemotherapy"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC1/2/3","id":"OG005","title":"IC1/2/3 Atezolizumab"}],"paramType":"NUMBER","populationDescription":"ORR analyses was performed on all randomized patients who had measureable disease at baseline","reportingStatus":"POSTED","timeFrame":"Up to approximately 25 months after first participant enrolled","title":"Percentage of Participants With Unconfirmed Objective Response Rate (ORR) as Determined by the Investigator With Use of Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}